Exploring The Role Of Tianeptine In Neuroplasticity Research

Disclaimer: For Research Use Only - Not for Human or Animal Consumption. This article is for educational and research purposes. Tianeptine is not approved by the FDA for any medical use. Nordic Chems supplies it for laboratory research only. Handle it under the regulations and institutional rules that apply to your laboratory.

Tianeptine is used in neuroplasticity research because published studies in rodent and tree shrew stress models report that it changes how neurons respond to stress. The reported effects fall into 5 areas: glutamate signaling, dendritic structure, synaptic potentiation, neurotrophins such as BDNF, and mitochondrial proteins. This article summarizes what those studies found, where the evidence is mixed, and what the current regulatory status means for laboratories.

Every finding below comes from preclinical work published by independent research groups. None of it describes a use in people. Nordic Chems supplies tianeptine research compounds for laboratory and analytical work only.

What Is Tianeptine? A Brief Overview for Researchers

Tianeptine is a tricyclic compound with a dibenzothiazepine core and a heptanoic acid side chain. Its chemical name is 7-[(3-chloro-6,11-dihydro-6-methyl-5,5-dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid. It was discovered and patented by the French Society of Medical Research in the 1960s.

Classical tricyclic compounds inhibit the reuptake of serotonin and norepinephrine. Tianeptine was first described as a serotonin reuptake enhancer, but a 2010 review in Molecular Psychiatry (McEwen et al., 2010) reported that it does not inhibit serotonin or norepinephrine uptake, has low affinity for the serotonin transporter, and that a serotonin-based explanation of its effects is doubtful. Research attention moved to glutamate signaling and, from 2014, to the μ-opioid receptor. For the full receptor picture, see our guide to tianeptine's mechanism of action in laboratory research.

Tianeptine at a glance:

• • Structural class: tricyclic, dibenzothiazepine core.
  • Salt forms used in research: sodium salt (CAS 30123-17-2) and sulfate.
  • Receptor target identified in vitro: μ-opioid receptor, full agonist.
  • Monoamine reuptake: no inhibition of serotonin or norepinephrine uptake reported.
  • FDA status: not approved for any medical use.
  • US federal scheduling: proposed for Schedule I on July 8, 2026. Not final as of October 13, 2026.
    
    

The Science of Neuroplasticity: Why It Matters

Neuroplasticity is the nervous system's capacity to change its structure and function in response to experience, injury and stress. Researchers separate it into 2 forms:

• Structural plasticity: physical change, such as dendritic branching, dendritic retraction, synaptic remodeling and the birth of new cells in the dentate gyrus.
• Functional plasticity: change in how circuits work, from shifts in synaptic strength, measured as long-term potentiation (LTP), to the reassignment of functions between regions after injury.

Stress models are a standard experimental route into this subject. In rats, repeated restraint or immobilization stress shortens and simplifies dendrites in hippocampal area CA3 and lengthens dendrites in the basolateral amygdala, and acute stress suppresses LTP in the hippocampus and prefrontal cortex. Those changes can be measured and repeated, which is why stress models are used in research on mood disorders, trauma-related disorders, neurodegeneration and aging, and why compounds that alter the changes are used as research tools.

Tianeptine’s Role in Neuroplasticity Research

Research Use Only: the findings below come from published animal and in vitro studies run by independent groups. They are summarized for scientific reference. Tianeptine supplied by Nordic Chems is not for administration to humans or animals.

Regulation of Glutamate Transmission

Glutamate is the brain's main excitatory neurotransmitter, and stress changes how it is released and cleared. 3 findings summarized in the McEwen et al. review describe how tianeptine interacts with that system:

• Extracellular glutamate: in rats, acute restraint stress raised extracellular glutamate in the basolateral and central nuclei of the amygdala. Tianeptine blocked the rise in the basolateral nucleus and left the central nucleus unchanged (Reznikov et al., 2007).
• NMDA and AMPA currents: in rats, 21 days of restraint stress enlarged the NMDA component of excitatory currents at hippocampal CA3 synapses. Tianeptine returned the ratio of NMDA to AMPA/kainate currents to control values (Kole et al., 2002).
• AMPA receptor phosphorylation: in rodents, 19 days of tianeptine administration increased phosphorylation of the GluR1 AMPA receptor subunit at Ser831 in the frontal cortex and in hippocampal CA3 and dentate gyrus, and at Ser845 in CA3 (Svenningsson et al., 2007).

The effect on glutamate receptors appears to be indirect. In receptor screening, tianeptine showed no appreciable direct activity at glutamate receptors at concentrations below 10 μM (Gassaway et al., 2014). Our article on tianeptine in glutamate receptor research covers AMPA, NMDA and mGluR work in more depth.

Dendritic Structure and Hippocampal Cell Proliferation

The structural findings are the oldest in this literature. In adult male rats, 21 days of daily restraint stress reduced the length and the number of branch points of CA3 pyramidal dendrites, and daily corticosterone injections did the same. Tianeptine given before each session prevented both effects (Watanabe et al., 1992). Later work in rats reported that tianeptine prevented the stress-linked increase in dendritic length in the basolateral amygdala (McEwen et al., 2010).

In tree shrews exposed to psychosocial stress, tianeptine prevented the stress-linked decreases in hippocampal volume, in the metabolite N-acetylaspartate, and in the proliferation of granule cell precursors in the dentate gyrus (Czéh et al., 2001). These studies report prevention or reversal of stress effects. They do not show growth beyond the unstressed baseline. For protocol-level detail, see tianeptine in hippocampal neuron studies.

Long-Term Potentiation

LTP is the standard laboratory measure of functional plasticity. In rats, tianeptine reversed the stress-induced suppression of primed-burst potentiation in hippocampal CA1 and increased potentiation in unstressed animals. It also reversed the stress-induced block of LTP in the pathway from the hippocampus to the prefrontal cortex. It did not change the stress-related increase in LTP in the basolateral amygdala (McEwen et al., 2010; Zoladz et al., 2008).

Influence on Brain-Derived Neurotrophic Factor (BDNF)

BDNF supports the growth and maintenance of neurons and is a standard marker in plasticity studies. The tianeptine data here are mixed:

• Repeated tianeptine administration increased BDNF in the rat amygdala in both stressed and unstressed animals. The same study found no change in hippocampal BDNF from stress or from tianeptine (Reagan et al., 2007, as summarized by Zoladz et al., 2008).
• The McEwen et al. review describes data suggesting that tianeptine increases BDNF and NGF gene expression in the hippocampus and amygdala, where stress lowers it.

Region matters. A protocol that measures BDNF in 1 region should not assume the result holds in another.

Mitochondrial Proteins and Energy Metabolism

Neurons have high energy demand, and stress models show changes in mitochondrial enzymes and proteins. 3 rat studies have examined tianeptine in this context:

• Enzyme activity: in rats that were not maternally deprived, 14 days of tianeptine increased the activity of respiratory chain complexes II and IV, citrate synthase and succinate dehydrogenase in the hippocampus (Della et al., 2013).
• Mitochondrial proteome: in a prenatal stress model, 21 days of tianeptine changed 16 protein spots in hippocampal mitochondria-enriched fractions. 14 of the 16 increased, including proteins of the Krebs cycle and the respiratory chain. The frontal cortex showed 3 changes (Głombik et al., 2016).
• Synaptic fractions: in rats kept in social isolation for 6 weeks, tianeptine during the final 3 weeks raised Krebs cycle, oxidative phosphorylation and antioxidant proteins in hippocampal synaptosomes and lowered proteins involved in synaptic vesicle endocytosis (Perić et al., 2021).

The 2 proteomic studies used 6 animals per group and males only. Neither measured mitochondrial respiration directly, so the functional meaning of the protein changes is an inference.

The μ-Opioid Receptor Link

In 2014, a receptor screening study identified tianeptine as a full agonist at the μ-opioid receptor (MOR), with a binding affinity (Ki) of 383 nM at the human receptor, weaker activity at the δ-opioid receptor and none at the κ-opioid receptor (Gassaway et al., 2014). The authors proposed that MOR activation is the first molecular step and that the glutamate effects follow from it. They presented this as a hypothesis to be tested.

A 2017 mouse study supported the receptor's role: the behavioral effects of tianeptine were absent in mice lacking MOR. In that study, repeated tianeptine did not produce the tolerance or naloxone-precipitated withdrawal seen with morphine, but it did produce conditioned place preference, a laboratory marker of reward. The studies cited here did not test whether MOR activation drives the structural plasticity findings above. MOR activity is also the basis of the regulatory concern described below.

Evidence Summary

The reported results, by measure:

• Extracellular glutamate: stress-induced rise blocked in the basolateral amygdala, unchanged in the central nucleus. Model: rat, acute restraint stress (Reznikov et al., 2007).
• NMDA to AMPA/kainate current ratio: returned to control values in CA3. Model: rat, 21 days of restraint stress (Kole et al., 2002).
• CA3 dendrite length and branch points: stress-induced reduction prevented. Model: rat, 21 days of restraint stress or corticosterone (Watanabe et al., 1992).
• Hippocampal volume and dentate gyrus cell proliferation: stress-induced decreases prevented. Model: tree shrew, psychosocial stress (Czéh et al., 2001).
• CA1 primed-burst potentiation: stress-induced suppression reversed. Model: rat, predator stress (McEwen et al., 2010).
• BDNF: increased in the amygdala, unchanged in the hippocampus. Model: rat, with and without stress (Reagan et al., 2007).
• Mitochondrial proteins: Krebs cycle and respiratory chain proteins increased in the hippocampus. Models: rat, prenatal stress and social isolation (Głombik et al., 2016; Perić et al., 2021).
• μ-opioid receptor: full agonist. Model: human and mouse receptors in cell assays (Gassaway et al., 2014).

Limits of the Evidence

• All structural and functional findings come from rats, mice or tree shrews. 3 of the studies cited here report using males only.
• Most results describe prevention or reversal of a stress effect. Effects in unstressed animals were reported for CA1 potentiation, amygdala BDNF and hippocampal enzyme activity.
• BDNF results differ by brain region.
• The proteomic studies used 6 animals per group and did not measure respiration.
• The link between MOR activation and the plasticity findings is a hypothesis, and the same receptor activity underlies the safety concerns documented by the FDA and DEA.
  
  

Regulatory Status as of October 2026

Tianeptine is not approved by the FDA for any medical use. The FDA states that it does not meet the statutory definition of a dietary ingredient and is not generally recognized as safe for use in food.

On July 8, 2026, the DEA published a proposed rule to place tianeptine, including its salts, in Schedule I of the Controlled Substances Act. The comment period closed on August 7, 2026. As of October 13, 2026, no final rule had been published in the Federal Register and no effective date had been set. The proposal names 15 states that had already controlled or banned tianeptine sales, and cites poison center data showing a 1,400 percent rise in tianeptine exposures from 2015 to 2023.

Confirm federal, state and institutional rules before ordering or handling tianeptine, and check the status of the proposed rule again at the time of purchase. Our state-by-state guide to tianeptine restrictions tracks the current list.

Ethical Research Use and Handling of Tianeptine

Formats and Documentation

Nordic Chems supplies tianeptine in 4 formats: tianeptine sodium powder (10 g), tianeptine sodium capsules (12.5 mg, 30 count), tianeptine sulfate capsules (30 count) and tianeptine sodium solution (50 mg/ml, 50 ml). Stated quantities are nominal reference values for documentation and inventory control.

Each tianeptine batch is tested by 2 independent laboratories, BioRegen Labs in Houston and Janoshik Analytical in Prague, using HPLC and mass spectrometry. Certificates of Analysis are published on the Quality Control page. Match the batch number on the container to the certificate before use.

Purchase Terms

Under the Nordic Chems Terms of Service, buyers must be at least 18 years old, must use products solely for research purposes, and must have them handled only by qualified and trained individuals. Nordic Chems may verify a buyer at its discretion and may refuse orders where misuse is suspected. Tianeptine is not sold to buyers in states that restrict it. The current list appears on each product page.

Safety Protocols and Best Practices

• Wear gloves, eye protection and a lab coat when handling the compound.
• Store containers sealed, cool and dry, with access limited to authorized personnel, and follow the storage guidance in the product documentation.
• Keep a usage log that records date, quantity, purpose and handler.
• Obtain the institutional approvals your work requires, and dispose of waste through your institution's chemical waste process.
• Train every handler in chemical safety before first use.

Summary

Published preclinical studies report that tianeptine prevents or reverses stress-linked changes in dendritic structure, hippocampal cell proliferation, glutamate signaling and synaptic potentiation in animal models. BDNF findings vary by brain region, the mitochondrial findings rest on small proteomic studies, and the role of the μ-opioid receptor in these effects is a working hypothesis. Tianeptine remains a research compound: it is not approved by the FDA, a federal scheduling proposal is pending, and Nordic Chems supplies it for laboratory research only.

Disclaimer: For Research Use Only - Not for Human or Animal Consumption. Tianeptine is not approved by the FDA for any medical use. Handle it under the regulations and institutional rules that apply to your laboratory.

FAQs

Is tianeptine safe for human use?

No. Tianeptine is not approved by the FDA for any medical use, and the FDA has received reports of severe adverse events linked to tianeptine products, including seizures, loss of consciousness and death. Nordic Chems supplies tianeptine strictly for laboratory research. It is not for human or animal consumption.

What does tianeptine do in neuroplasticity research models?

In published rat, mouse and tree shrew studies, tianeptine prevented or reversed stress-linked changes in CA3 dendritic structure, dentate gyrus cell proliferation, glutamate signaling and long-term potentiation. These are preclinical findings from animal models and do not describe a use in people.

Does tianeptine increase BDNF?

Results vary by brain region. In 1 rat study, repeated tianeptine administration raised BDNF in the amygdala and left hippocampal BDNF unchanged. A 2010 review describes data suggesting increased BDNF and NGF gene expression in the hippocampus and amygdala. Measure the region your protocol targets instead of assuming a general effect.

Is tianeptine a controlled substance in the United States?

Not at the federal level as of October 13, 2026. The DEA proposed placing tianeptine and its salts in Schedule I on July 8, 2026, the comment period closed on August 7, 2026, and no final rule had been published by October 13, 2026. The DEA proposal names 15 states that already control or ban tianeptine sales. Confirm current federal and state rules before ordering.

Can tianeptine from Nordic Chems be used in animal studies?

No. Tianeptine from Nordic Chems is supplied for laboratory research and analytical use and is not intended for administration to humans or animals. The animal findings summarized in this article come from published studies by independent research groups.

What precautions apply when handling tianeptine?

Wear gloves, eye protection and a lab coat. Store the compound sealed, cool and dry in a labeled container with access limited to trained personnel. Follow your institution's chemical safety protocols and keep a usage and storage log.